Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 11, 2022

SELL
$29.67 - $60.28 $56,373 - $114,532
-1,900 Reduced 12.5%
13,300 $516,000
Q2 2021

Aug 03, 2021

BUY
$67.25 - $92.52 $121,050 - $166,536
1,800 Added 13.43%
15,200 $1.32 Million
Q3 2020

Nov 13, 2020

BUY
$30.41 - $40.5 $88,189 - $117,450
2,900 Added 27.62%
13,400 $536,000
Q2 2020

Aug 13, 2020

BUY
$20.21 - $35.23 $212,205 - $369,914
10,500 New
10,500 $360,000

Others Institutions Holding FATE

About FATE THERAPEUTICS INC


  • Ticker FATE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,000,304
  • Market Cap $99.9M
  • Description
  • Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...
More about FATE
Track This Portfolio

Track Handelsbanken Fonder Ab Portfolio

Follow Handelsbanken Fonder Ab and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Handelsbanken Fonder Ab, based on Form 13F filings with the SEC.

News

Stay updated on Handelsbanken Fonder Ab with notifications on news.